pumitamig

News

Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.

News

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.